JFC [JPMORGAN CHINA REGION FUND,] NSAR-B: (Original Filing)
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
[EX-99.77B ACCT LTTR 2 jfchinaauditletter.htm]
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
[jfchinaauditletter.htm 2 EX-99.77B ACCT LTTR]
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
[Biostar Pharmaceuticals, Inc. Announces 2010 Guidance: Revenues of $69 to $71 million and Net Income $16.2 to $17 million XIANYANG, China, March 1, 2010 (Xinhua-PRNewswire-FirstCall) Biostar forecasts revenues of $69.0 to $71.0 million with net income of $16.2 million to $17 million, excluding any non-cash charges. Management anticipates sales of its flagship product, Xin Aoxing, will represent approximately 68% to]
[Perfect World Co., Ltd. ELVIN ING EE AU Kelvin Wing Kee Lau Chief Financial Officer 2]
[Perfect World Co., Ltd. ELVIN ING EE AU Kelvin Wing Kee Lau Chief Financial Officer 2]
[American Lorain Corporation March 1, 2010 VIA EDGAR AND FEDERAL EXPRESS Mr. Anne Nguyen Parker Re: American Lorain Corporation Dear Ms. Parker: On behalf of American Lorain Corporation ("we" or the "Company"), we respond as follows to the Staff's comment letter dated February 19, 2010 relating to the above-captioned registration statement on Form S-3. Captions and page references herein correspond]
[American Lorain Corporation March 1, 2010 VIA EDGAR AND FEDERAL EXPRESS Mr. Anne Nguyen Parker Re: American Lorain Corporation Dear Ms. Parker: On behalf of American Lorain Corporation ("we" or the "Company"), we respond as follows to the Staff's comment letter dated February 19, 2010 relating to the above-captioned registration statement on Form S-3. Captions and page references herein correspond]